Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Supercharged t cells take on deadly brain tumors

NCT ID NCT06815432

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 30 times

Summary

This early-phase trial tests a new treatment for adults with a returning type of brain cancer called glioblastoma. The treatment uses the patient's own immune cells (T cells) that are genetically modified in a lab to recognize and attack cancer cells that carry a specific protein (GPC3). The cells also include a safety switch that can be activated to stop them if serious side effects occur. The main goal is to check the safety of this approach and find the right dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME OF BRAIN are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Baylor St. Luke's Medical Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.